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Background: Escherichia coli and Klebsiella pneumoniae are the major bacterial pathogens being isolated and
reported from mid stream urine (MSU) specimens, globally. These uropathogens are mostly implicated as the major
extended spectrum beta-lactamase (ESBL) producers, severely limiting the therapeutic management in cases of
urinary tract infections. Limited studies had been reported from Nepal investigating the ESBL producers among
uropathogens. This study was designed to assess the prevalence of ESBL producing E.coli and K. pneumoniae in
urinary isolates at a centrally located major tertiary care hospital in Kathmandu valley, Nepal.
Methods: Between September 2011 and May 2012, during the nine months period, 6308 MSU specimens were
collected aseptically from the same number of clinically suspected patients of urinary tract infections. The samples
were cultured on MacConkey agar and blood agar. The isolates with significant bacteriuria (105 CFU / ml) were
identified based on standard laboratory procedures. Antimicrobial susceptibility tests were carried out using various
antimicrobial discs alongwith ceftriaxone on E.coli and K. pneumoniae isolates by Kirby Bauer disc diffusion method
as per the recommendations of CLSI. On initial screening with ceftriaxone (30 μg) disc showing resistance was then
confirmed for ESBL production by phenotypic confirmatory disc diffusion test (PCDDT) using ceftazidime (30 ug)
and ceftazidime + clavulanic acid (30 μg + 10ug) disc as per guidelines of CLSI (2011).
Results: Out of a total of 6308 MSU specimens investigated for significant bacteriuria, E.coli isolates were 444
(7.04%) and K.pneuminiae were 145 (2.3%) making a total of 589 (9.34%). Initial screening with ceftriaxone disc
revealed 155 isolates of E.coli and 70 isolates of K.pneumoniae to be resistant. Further testing by PCDDT method
showed 60/444 (=13.51%) of E. coli and 24/145 (=16.55%) of K. pneumoniae isolates to be confirmed ESBL
producers. These ESBL – producer uropathogens showed high degree of resistance to ceftriaxone (100.0%),
amoxycillin, fluoroquinolones and co-trimoxazole.
Conclusion: An emerging and moderately high prevalence of ESBL-producing E. coli and K. pneumoniae was observed
and confirmed in the urinary isolates investigated. It is essential to have a regular and routine monitoring of ESBL
producing clinical isolates in laboratory practice.
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Antimicrobial resistance among bacterial strains is an
emerging problem, worldwide. Urinary tract infections
(UTIs) are one of the most common bacterial infections
in humans both in the community and the hospital set-
tings [1-3]. Escherichia coli and Klebsiella pneumoniae
are the two pre-dominant pathogens commonly isolated in
urine. These uropathogens have also developed resistance
to commonly prescribed antimicrobial agents, This severely
limits the treatment options of an effective therapy.
Primarily, these uropathogens exerts their antimicrobial
resistance against beta-lactams by producing extended
spectrum beta-lactamases (ESBLs) enzymes that confers
bacterial resistance to all beta-lactams except carba-
penems, cephamycins and clavulanic acid [4-6]. ESBLs
are class A beta-lactamases, and are plasmid-mediated
enzymes that hydrolyze oxyimino-cephalosporins and
monobactams, with various genotypes such as SHV, TEM,
CTX-M, VEB, PER, BEL-1, BES-1, TLA and IBC [7,8].
Further, plasmids carrying ESBLs are transferable from
one bacterial strain to the next and between different
bacterial species [8]. ESBLs are clinically significant and
when detected, indicate the need for the use of appropri-
ate antibacterial agents. The mortality rate in misdiag-
nosed patients with ESBLs producing UTIs have ranged
from 42-100% [9-11]. Antibacterial choice is often compli-
cated by multi-resistance. There is an increasing associ-
ation between ESBL production and fluoroquinolone
resistance [12,13] and aminoglycoside resistance [14].
Multi-drug resistance (MDR) among ESBL expressing
strains is complex and is influenced by the location of
resistance genes on integrons that possess promoters that
drive the co-ordinated expression of downstream resist-
ance cassettes [15]. Thus, multi-resistance has severely
limited the treatment options for ESBLs producing strains
of Enterobacteriaceae. More recently, the emergence of
carbapenem resistance has been reported among ESBL
producing organisms [8].
The prevalence of bacteria producing ESBLs varies
world-wide, with reports from North America, Europe,
South America, Africa and Asia [16-18]. There is ample
evidence to suggest the spread of ESBL infections is
higher in resource poor countries [19,20].
Limited number of studies had been reported in this
regard from Nepal [21-23]. This study was thus designed
to estimate the current prevalence and antimicrobial
resistance patterns among ESBL producing urinary isolates
of E.coli and K.pneumoniae in a centrally located tertiary
care centre in Kathmandu valley, Nepal.
Methods
Setting
This investigation was carried out in the Department
of Microbiology, Kathmandu Medical College TeachingHospital (affiliate Kathmandu University), a tertiary
healthcare facility centrally located in the capital city of
Kathmandu, Nepal. Ethical approval was not required
to carry out this work as the bacterial isolates were col-
lected as part of standard patient care investigation.
Specimens
Between 1st September 2011 and 31st May 2012, 6308
consecutive and non-duplicate mid-stream urine speci-
mens were collected aseptically from clinically suspected
patients of UTIs attending outpatient and inpatient de-
partments (medicine, surgery, paediatrics and gynecology
and obstetrics) of the hospital. Urine specimens were
transported to the Department of Microbiology laboratory
and processed immediately.
Inclusion criteria
Patients who did not have a course of antibiotics at least
two weeks prior to selection in the study.
Identification of isolates
The urine sample was cultured on to MacConkey agar
and blood agar plates and incubated at 37°C for 24 hours
and the colonies identified based on morphology and
gram negative bacilli isolated were characterized by per-
forming gram’s staining, motility and standard biochem-
ical tests [24].
Anti-microbial susceptibility testing
E.coli and K. pneumoniae isolates were selected to deter-
mine their susceptibility patterns against the first line
antimicrobial agents, by the disc diffusion method of
Kirby- Bauer as described by Clinical Laboratory Stan-
dards Institute (CLSI) [25]. The antimicrobial agents used
were: amikacin (30 μg), gentamicin (10 μg), ofloxacin
(5 μg), norfloxacin (10 μg), nitrofurantoin (300 μg), amoxi-
cillin (10 μg), nalidixic acid (30 μg), co-trimoxazole (1.25/
23.75 μg) and ceftriaxone (30 μg).
Screening of ESBL producing strains of E.coli and
K.pneumoniae
Strains showing zone of inhibition of ≤ 25 mm for ceftri-
axone were selected for confirmation test of ESBL, ac-
cording to guidelines of CLSI [25].
Phenotypic Confirmatory Disc Diffusion Test (PCDDT)
for ESBL
The potential ESBL producing strains of E.coli and
K.pneumoniae were confirmed for ESBL production by
phenotypic test. Briefly, a lawn culture of the isolated
bacteria on Mueller Hinton agar (MHA) was made and
ceftazidime (30 μg) and the combination disc ceftazidime +
clavulanic acid (30 μg + 10 μg) was placed with 25 mm
apart. An increase of ≥ 5 mm in zone of inhibition for
Table 2 Age groups and sex-wise details of patients with




ESBL positive E.coli ESBL positive K.pneumoniae
M F Total M F Total
< 15 6 2 8 0 0 0
16-30 2 20 22 2 10 12
31-45 8 10 18 1 1 2
46-60 2 2 4 2 2 4
>60 6 2 8 4 2 6
Total 24 36 60 9 15 24
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alone was confirmed as ESBL producing strains, as per rec-
ommendations of CLSI [25]. ESBL positive strains of E.coli
and K. pneumoniae were selected to determine their sus-
ceptibility patterns against the second line of antimicrobial
agent (imipenem −10 μg), by the disc diffusion method of
Kirby- Bauer as described by the CLSI [25]. The antimicro-
bial agents disc were obtained from Hi-Media Laboratories
Pvt. Ltd., Mumbai, India. E.coli ATCC 25922 (ESBL nega-
tive) and K.pneumoniae ATCC 700603 (ESBL positive)
were used as controls throughout the study.
All data were analyzed using SPSS statistical software
(SPSS Inc., Chicago, IL).
Results
Out of a total of 6308 mid-stream urine specimens
screened for significant bacteriuria, a total of 444 (7.03%)
and 145 (2.29%) isolates of E.coli and K.pneumoniae were
confirmed, respectively. Initial screening of these isolates
for ESBL production showed 155/ 444 of E.coli and 70/
145 of K.pneumoniae strains to be ceftriaxone resistant.
Confirmation test (PCDDT) revealed 60/444 (13.51%) of
E.coli and 24/145 (16.55%) of K.pneumoniae isolates to be
ESBL positive (Table 1). A high rate of non-ESBL medi-
ated ceftriaxone resistance was observed i.e. (95/155 =
63.33%) for E.coli and (46/70 = 65.71%) for K.pneumoniae
isolates.
The age varied from 7 months to 72 years and the sex
ratio male:female was (1:2), of the patients from whom
E.coli was isolated. The age range was 17 years to
70 years and the sex ratio male:female was (1:2.4) of the
patients from whom K.pneumoniae was isolated. Clearly,
the female group constituted the majority of the patients
(Table 2).
A wide spectrum of resistance patterns to various anti-
microbial agents was shown by the ESBL positive E.coli
and K.pneumoniae strains. These E.coli strains showed a
high degree of resistance (> 80%-95%) to ofloxacin, nor-
floxacin, co-trimoxazole, nalidixic acid and amoxicillin.
The E.coli strains were much less resistant to gentamicin
(23.33%), nitrofurantoin (11.66%) and least resistant to
amikacin (6.66%).
K.pneumoniae isolates were maximally resistant (100%)
to amoxicillin. A moderately high resistance of 66.66%,
58.33% and 45.83% were shown to nalidixic acid,
co-trimoxazole and gentamicin, respectively by theseTable 1 ESBL pattern of E.coli and Klebsiella pneumoniae isola
Bacterial
sp. isolated






E.coli 444/6308 (7.03) 155
K.pneumoniae 145/6308 (2.29) 70K. pneumoniae strains. Moderate resistance of 37.5% and
29.16% were shown toward the fluoroquinolone drugs
norfloxacin and ofloxacin. Nitrofurantoin (20.83% resistan-
tance) and amikacin (12.5% resistance) were the most
effective antimicrobial agents against ESBL producing
K.pneumoniae isolates. All the E.coli and K.pneumoniae
isolates were susceptible (100%) to the carbapenem, imi-
penem (Table 3).
A high multi-drug resistance (defined as resistant to ≥ 3
different classes of antimicrobial agents) of 91.66% and
87.5% respectively was observed among the ESBL produ-
cing strains of E.coli and K.pneumoniae. None of the
strains of ESBL positive E.coli and K.pneumoniae were
found to be sensitive to all the antimicrobial agents tested
(Table 4).
Discussion
There is a paucity of documented literature on investiga-
tion of ESBLs producing uropathogens from Nepal [23].
To the best of our knowledge this is the first report from
Nepal with an exclusive focus on investigating the current
prevalence and antimicrobial susceptibility patterns among
ESBL producing E. coli and K. pneumoniae – the predom-
inant uropathogens, globally. The urine culture positivity
rate was 9.32% (E.coli =7.03% and K.pneumoniae = 2.29%),
which was low compared to that reported from South
Africa (51%) [26]. Nicaragua (30%) [27] and India (39%)
[28]. ESBL production was more prevalent in K.pneumo-
niae strains, as compared to that in E.coli strains, which
agrees with findings reported in previous studies [13,29].
The occurrence of ESBLs among clinical isolates vary
greatly worldwide and geographically and are rapidlyted from urine specimens
of screened and selected
ates for ESBL confirmatory
(ceftriaxone resistant)
No. of isolates confirmed




Table 3 Antimicrobial resistance patterns of confirmed
ESBL producing E.coli and K.pneumoniae isolates from
urine specimens
Antibiotic ESBL positive
E.coli (n = 60)
ESBL positive
K.pneumoniae (n = 24)
T/ R (%) T/R (%)
Amikacin 60/04 (6.66) 24/3 (12.5)
Gentamicin 60/14 (23.33) 24/11 (45.83)
Ofloxacin 60/49 (81.66) 24/07 (29.16)
Norfloxacin 60/54 (90.0) 24/9 (37.5)
Nitrofurantoin 60/07 (11.66) 24/05 (20.83)
Amoxycillin 60/57 (95.0) 24/24 (100.0)
Nalidixic acid 60/57 (95.0) 24/16 (66.66)
Co-trimoxazole 60/51 (85.0) 24/14 (58.33)
Ceftriaxone 60/60 (100.0) 24/24 (100.0)
Ceftazidime 60/60 (100.0) 24/24 (100.0)
Imipenem 60/0 (0.0) 24/0 (0.0)
T = Total no. of isolates tested; R = No. of isolates resistant.
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13.51% and K.pneumoniae= 16.55%). It was low as com-
pared to a study done in India [30], which reported nearly
40% of urinary isolates of E.coli and K.pneumoniae were
ESBL positive. The highest isolation rate of ESBLs produ-
cing K.pneumoniae had been reported from the Latin
America (54.4%), the western Pacific (24.6%) and Europe
(22.6%). The frequency of ESBL producing E.coli in these
areas was reported to be 8.5%, 7.8% and 5.3%, respectively
[31]. Females showed a higher rate of isolation of ESBL
producing E.coli (60%) and K.pneumoniae (62.5%), which
parallels the findings as reported earlier [32,33]. This study
revealed a higher occurrence of ESBL producing uropatho-
gens in the adult age group of 16–45 years, which is similar
to that reported in a study done in Pakistan [1].
The high rates for non – ESBL mediated ceftriaxone
resistant E.coli (63.33%) and K.pneumoniae (65.71%)
isolates may be due to their different mechanisms for
resistance such as the production of ampC β lactamase,
metallo-betalactamase, etc. [34]. This further limits the
therapeutic options available to treat these infections.Table 4 Antimicrobial resistance patterns among ESBL













5 (8.34) 3 (12.5) 2
55(91.66) 21 (87.5) ≥3The susceptibility patterns of the ESBL producing
E.coli and K. pneumoniae varied widely with the class of
antimicrobial agents used. All isolates were uniformly
resistant (100%) to the third generation cephalosporin,
ceftriaxone. All ESBL positive K.pneumoniae strains
were resistant (100%) to amoxicillin, while resistance
rate for ESBL positive E.coli was 95%. In a study re-
ported from Madagascar [35], 80%of the E.coli isolates
were resistant to amoxicillin. In our study E.coli showed
a high resistance rate (85%) to co-trimoxazole where as
the K.pneumoniae showed resistance rate (58.33%) to
co-trimoxazole. A comparable resistance rate of 80% and
45% to co-trimoxazole was shown among ESBL produ-
cing E.coli and K.pneumoniae isolates in a study con-
ducted in Iran [36]. A striking feature in this study was
that the quinolones, ofloxacin, norfloxacin and nalidixic
acid demonstrated a high resistance varying from > 80%
to 95% among ESBL positive E.coli, while 29.16% to
66.66% of K. pneumoniae were resistant. This parallels
with the findings of the studies done in Indore, India
[37] and Bangladesh [38]. A lower resistance rates vary-
ing from 24% to 44% to norfloxacin had been reported
in European countries [39]. This probably reflects a bet-
ter management of these clinically significant infections
in resource-rich countries.
Conversely, this study revealed resistance rates of
45.83% and 12.5% to the aminoglycosides, gentamicin
and amikacin by ESBL positive K.pneumoniae strains. In
comparison, E.coli shown a much low resistance rate -
gentamicin (23.33%) and amikacin (6.66%). In contrast.
K. pneumoniae showed resistance to gentamicin (69%)
and amikacin (38%) while 59% and 33% resistance rates
were shown by E.coli isolates in a study done in Indore,
India [37]. A resistance rate of 46.7% to gentamicin was
shown by K.pneumoniae isolates in a report from Karachi,
Pakistan [40], which is similar to results in this study. This
report supports that aminoglycosides have good activity
against clinically important gram negative bacilli [41]. The
resistance rates of ESBL positive E.coli and K.pneumoniae
to nitrofurantoin were 11.66% and 20.83%, respectively.
Parallel resistance rate (12%) by E.coli isolates was shown
in a report from Indore, India [37].
A significant finding in this report was that aminogly-
cosides and nitrofurantoin proved to be the optimal
drugs. This may be due to the restricted use of these
drugs in our hospital setting and nitrofurantoin is usu-
ally reserved to be prescribed only in cases of UTIs since
it is excreted and concentrated in urine. All ESBL posi-
tive E.coli and K.pneumoniae strains in this study were
sensitive (100%) to imipenem. A very high MDR rates
of 91.66% and 87.5% among ESBL positive E.coli and
K.pneumoniae were obtained in this study. A compar-
able MDR rate of 83% among E.coli isolates was re-
ported in a study done in Peshawar, Pakistan [1].
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sparsely-populated areas mainly in hilly and mountain-
ous regions, severely limited health-care resources and a
low-income economy. And the health care facilities are
concentrated in the capital city of Kathmandu and
people come here for treatment, from far-flung areas of
the country.These people may acquire pathogens and
when they return to their native areas in villages, may
act as carriers of drug resistant pathogens.
Multi-center studies involving major health-care facil-
ities in other parts of the country are required to have a
more clear picture of ESBL producing uropathogens.
Further, molecular epidemiological studies of resistance
genes among the uropathogens would provide us much
needed details on bacterial clones circulating in this
region.
Conclusion
This report documents the emergence and occurrence
of ESBL producing E.coli and K.pneumoniae in urinary
isolates in Nepal. A moderately high prevalence of ESBL
producing E.coli and K.pneumoniae was observed and
confirmed in the urinary isolates. A strict hospital infec-
tion control policies and a prudent anti-microbials use
regimens are to be adopted by the physicians. It is essen-
tial and mandatory to have a regular and routine moni-
toring of ESBL producing clinical isolates in clinical
laboratories.
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